Bente Glintborg

Bente Glintborg

Glostrup, Denmark

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 148 publications

The impact of smoking and obesity on secukinumab effectiveness in psoriatic arthritis: real-world evidence from 1202 European patients.

The impact of smoking and obesity on secukinumab effectiveness in psoriatic arthritis: real-world evidence from 1202 European patients.

Journal: EULAR rheumatology open
Published: June 29, 2026

Biological tapering is cost-effective in patients with inflammatory arthritis in the biosimilar era: secondary analyses on the randomised BIODOPT trial.

Biological tapering is cost-effective in patients with inflammatory arthritis in the biosimilar era: secondary analyses on the randomised BIODOPT trial.

Journal: EULAR rheumatology open
Published: June 29, 2026

On the edge of dependency: how older adults with rheumatoid arthritis experience living with frailty.

On the edge of dependency: how older adults with rheumatoid arthritis experience living with frailty.

Journal: EULAR rheumatology open
Published: June 29, 2026

Differential joint-level response to secukinumab in psoriatic arthritis: A collaborative European observational cohort study.

Differential joint-level response to secukinumab in psoriatic arthritis: A collaborative European observational cohort study.

Journal: EULAR rheumatology open
Published: June 29, 2026

Overall and Sex-Specific Predictors of Secukinumab Effectiveness in European Patients With Psoriatic Arthritis: Results From the EuroSpA Collaboration.

Overall and Sex-Specific Predictors of Secukinumab Effectiveness in European Patients With Psoriatic Arthritis: Results From the EuroSpA Collaboration.

Journal: The Journal of rheumatology
Published: June 15, 2026

Overall and sex-specific predictors of secukinumab effectiveness in European patients with psoriatic arthritis: results from the EuroSpA collaboration.

Overall and sex-specific predictors of secukinumab effectiveness in European patients with psoriatic arthritis: results from the EuroSpA collaboration.

Journal: The Journal of rheumatology
Published: June 15, 2026

Site-specific articular response to TNF inhibitor in axial spondyloarthritis: a European cohort study.

Site-specific articular response to TNF inhibitor in axial spondyloarthritis: a European cohort study.

Journal: Joint bone spine
Published: May 13, 2026

Site-specific articular response to TNF inhibitor in axial spondyloarthritis: A European cohort study.

Site-specific articular response to TNF inhibitor in axial spondyloarthritis: A European cohort study.

Journal: Joint bone spine
Published: May 13, 2026

Difficult-to-manage and treatment-refractory psoriatic arthritis in patients treated with biological and targeted synthetic DMARDs: prevalence and characteristics in 5 Nordic registries.

Difficult-to-manage and treatment-refractory psoriatic arthritis in patients treated with biological and targeted synthetic DMARDs: prevalence and characteristics in 5 Nordic registries.

Journal: Annals of the rheumatic diseases
Published: February 20, 2026

Influence of national socioeconomic status on treatment retention and disease activity in psoriatic arthritis and axial spondyloarthritis: evidence over 2 years in 13 European countries.

Influence of national socioeconomic status on treatment retention and disease activity in psoriatic arthritis and axial spondyloarthritis: evidence over 2 years in 13 European countries.

Journal: Annals of the rheumatic diseases
Published: February 11, 2026

Impact of C reactive protein on effectiveness of interleukin-17 and tumour necrosis factor inhibitors in axial spondyloarthritis: a Danish nationwide observational study.

Impact of C reactive protein on effectiveness of interleukin-17 and tumour necrosis factor inhibitors in axial spondyloarthritis: a Danish nationwide observational study.

Journal: RMD open
Published: February 02, 2026

Impact of cardiometabolic comorbidities on clinical characteristics, prescription patterns and retention rate of first b/tsDMARD treatment in 5299 European real-world patients with psoriatic arthritis.

Impact of cardiometabolic comorbidities on clinical characteristics, prescription patterns and retention rate of first b/tsDMARD treatment in 5299 European real-world patients with psoriatic arthritis.

Journal: RMD open
Published: October 28, 2025
Showing 1-12 of 148

Last Updated: 09/26/2026